Jesús Gómez-Navarro

Author

Jesús Gómez-Navarro

Also Known As

J Gomez-Navarro, J Gómez-Navarro, J. Gomez-Navarro, J. Gómez-Navarro, J. Gómez‐Navarro, Jesus -. Gomez-Navarro, Jesus Gomez-Navarro, Jesus Gomez‐Navarro, Jesús Gómez-Navarro, Jesús Gomez‐Navarro

104

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Alabama at Birmingham University of California, Los Angeles The University of Texas MD Anderson Cancer Center UCLA Jonsson Comprehensive Cancer Center

About

Jesús Gómez-Navarro is an author at Pfizer (United States) specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.2K
2	Health Sciences	3	3	44
3	Engineering	1	1	60
4	Biochemistry	1	1	71
5	Biomedical Engineering	1	1	60

Jesús Gómez-Navarro

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Antoni Ribas, Richard Kefford, Margaret Marshall, Journal of Clinical Oncology	2013	811
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206 Antoni Ribas, Luis H. Camacho, Gabriel Lopez‐Berestein, Journal of Clinical Oncology	2005	584
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma Luis H. Camacho, Scott Antonia, Jeffrey A. Sosman, Journal of Clinical Oncology	2009	314
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer Ki Y. Chung, Ira Gore, Lawrence Fong, Journal of Clinical Oncology	2010	303
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma John M. Kirkwood, Paul Lorigan, Peter Hersey, Clinical Cancer Research	2010	238
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma Antoni Ribas, Begoña Comı́n-Anduix, Bartosz Chmielowski, Clinical Cancer Research	2009	208
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Ronald D. Alvarez, Mack N. Barnes, Jesús Gómez-Navarro, PubMed Gene TherapiesGene Transfer/expressionMedicineImmunologyHuman Ovarian Cancer	2000	161
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma A. Ribas, Axel Hauschild, Richard Kefford, Journal of Clinical Oncology Tremelimumab 15Tremelimumab ArmImmunologyImmunoeditingImmunotherapeutics	2008	156
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans Rong Huang, Jason Jalil, James S. Economou, Clinical Cancer Research	2011	151
Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma James M. Reuben, Bang‐Ning Lee, Changping Li, Cancer	2006	144

Page 1